|
1. Biologie
|
|
|
High-res biomolecule imaging [MIT News]
|
|
|
|
|
|
A
new method developed by researchers at MIT could lead to a way of
producing high-resolution images of individual biomolecules without
requiring crystallization, and it could even allow zoomed-in imaging of
specific sites within the molecules.
|
|
|
|
|
|
|
The genomics of cervical cancer [NIH]
|
|
|
|
|
|
To
gain new insights into cervical cancer, researchers with The Cancer
Genome Atlas (TCGA) Research Network analyzed the genomes of 178 primary
cervical cancers.
|
|
|
|
|
|
|
2.7 Etiologie - Obésité
|
|
|
|
|
3.4 Chimioprévention
|
|
|
|
4.12 Biopsies liquides
|
|
|
Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Report 2017 [ReportsnReports]
|
|
|
|
|
|
This
report studies sales (consumption) of Circulating Tumor Cells (CTCs)
and Cancer Stem Cells (CSCs) in Europe market, especially in Germany,
France, UK, Russia, Italy, Spain and Benelux, focuses on top players in
these countries, with sales, price, revenue and market share for each
player.
|
|
|
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
5. Traitements
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
Celgene co-founder Sol Barer bags a Johns Hopkins immuno-oncology spinout in buyout [EndPoints]
|
|
|
|
|
|
A
few weeks ago, Johns Hopkins Professor Jonathan Schneck published new
research showing how the biomimetic nano beads he had created in the lab
could work with a checkpoint inhibitor in fighting cancer. That work
Schneck did is held by a Johns Hopkins biotech spinout he created called
NexImmune, which Celgene co-founder and serial biotech startup master
Sol Barer just acquired.
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
6.11 Patients
|
|
|
|
6.6 Publications
|
|
|
|
6.9 Controverses
|
|
|
The Soon-Shiong Hype Machine [In the Pipeline]
|
|
|
|
|
|
This
is a crazily hard field to make progress in, and claiming that you’re
just making these incredible strides every day of the week is not doing
anyone any good – well, unless your name is Patrick Soon-Shiong.
|
|
|
|
|
|